The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
The glycosylation in SARS-CoV-2 and its receptor ACE2
Y Gong, S Qin, L Dai, Z Tian - Signal Transduction and Targeted …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), a highly infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …
Vaccines for COVID-19: a systematic review of immunogenicity, current development, and future prospects
Z Zhang, Q Shen, H Chang - Frontiers in immunology, 2022 - frontiersin.org
The persistent coronavirus disease 2019 (COVID-19), characterized by severe respiratory
syndrome, is caused by coronavirus 2 (SARS-CoV-2), and it poses a major threat to public …
syndrome, is caused by coronavirus 2 (SARS-CoV-2), and it poses a major threat to public …
Bioactive compounds from mangosteen (Garcinia mangostana L.) as an antiviral agent via dual inhibitor mechanism against SARSCoV-2: an in silico approach
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the virus that causes
COVID-19 which is responsible for respiratory illness infection in humans. The virus was first …
COVID-19 which is responsible for respiratory illness infection in humans. The virus was first …
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
S Kakavandi, I Zare, M VaezJalali, M Dadashi… - Cell Communication and …, 2023 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is caused by a new member of the
Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS …
Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS …
Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates
L Rodrigues, R Bento Cunha, T Vassilevskaia… - Molecules, 2022 - mdpi.com
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the …
A review of SARS-CoV-2 disease (COVID-19): pandemic in our time
N Al-Awwal, F Dweik, S Mahdi, M El-Dweik… - Pathogens, 2022 - mdpi.com
Development and deployment of biosensors for the rapid detection of the 2019 novel severe
acute respiratory syndrome—coronavirus 2 (SARS-CoV-2) are of utmost importance and …
acute respiratory syndrome—coronavirus 2 (SARS-CoV-2) are of utmost importance and …
SARS‐CoV‐2 papain‐like protease: structure, function and inhibition
Emerging variants of SARS‐CoV‐2 and potential novel epidemic coronaviruses underline
the importance of investigating various viral proteins as potential drug targets. The papain …
the importance of investigating various viral proteins as potential drug targets. The papain …
Basic virology of SARS-CoV 2
V Ravi, S Saxena, PS Panda - Indian journal of medical microbiology, 2022 - Elsevier
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly
transmissible pathogenic coronavirus emerged in late 2019 causing a pandemic of acute …
transmissible pathogenic coronavirus emerged in late 2019 causing a pandemic of acute …
Accelerating COVID-19 research using molecular dynamics simulation
The COVID-19 pandemic has emerged as a global medico-socio-economic disaster. Given
the lack of effective therapeutics against SARS-CoV-2, scientists are racing to disseminate …
the lack of effective therapeutics against SARS-CoV-2, scientists are racing to disseminate …